High Prevalence of Chronic Fatigue in Adult Long-Term Survivors of Acute Lymphoblastic Leukemia and Lymphoma During Childhood and Adolescence
|
|
- Rodney Williamson
- 6 years ago
- Views:
Transcription
1 JOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY Volume 2, Number 1, 2013 ª Mary Ann Liebert, Inc. DOI: /jayao Original Article High Prevalence of Chronic Fatigue in Adult Long-Term Survivors of Acute Lymphoblastic Leukemia and Lymphoma During Childhood and Adolescence Hanne Hamre, MD, 1 Bernward Zeller, MD, 2 Adriani Kanellopoulos, MD, 2 Cecilie E. Kiserud, MD, PhD, 1 Svend Aakhus, MD, PhD, 3 May B. Lund, MD, PhD, 4 Jon H. Loge, MD, PhD, 1,5 Sophie D. Fosså, MD, PhD, 6 and Ellen Ruud, MD, PhD 2 Purpose: Chronic fatigue (CF) is a frequent late effect of cancer, but has been poorly studied in adult survivors of childhood cancer. This cross-sectional study compares the prevalence of CF among adult survivors (childhood leukemia/lymphoma survivors; CLSs) of childhood acute lymphoblastic leukemia (ALL), Hodgkin lymphoma (HL), and non-hodgkin lymphoma (NHL) to controls, and explored CF s association with disease characteristics, treatment, mental and somatic late effects, and selected markers of low-grade inflammation. Methods: A total of 143 male and 147 female CLSs participated in this study, which comprised a questionnaire, clinical examination, and blood samples. The control group consisted of 1405 individuals from the Norwegian general population. The Chalder Fatigue Questionnaire assessed CF. Results: Median age at survey and observation time was 29.6 years and 21.1 years, respectively. The prevalence of CF was 27% among CLSs (ALL 22%, NHL 30%, HL 34%) versus 8% among controls. Compared to controls and adjusting for age and sex, the probability of having CF among CLS was elevated (odds ratio [OR] = 4.5; 95% confidence interval [CI]: ). In lymphoma survivors, presence of B-symptoms at diagnosis predicted CF in univariate analysis. Elevated levels of anxiety and depression predicted CF in multivariate analysis. Disease characteristics and treatment or somatic late effects were not associated with CF. Leukocyte, neutrophil, and trombocyte counts were elevated among subjects with CF. Conclusion: At a median of 20 years after diagnosis, the prevalence of CF in CLSs is more than three times that of the general population. A persistent low-grade inflammatory response may be involved in the pathogenesis of CF. Keywords: acute lymphoblastic leukemia, childhood lymphoma, chronic fatigue, Hodgkin lymphoma, inflammation, long-term effects, non-hodgkin lymphoma Fatigue is a frequent late effect of cancer treatment, and is defined as a persistent, subjective experience of tiredness, exhaustion, and lack of energy that is not relieved by rest. 1 While acute fatigue is a common symptom in all phases of the cancer trajectory, chronic fatigue (CF) is defined as persistent or relapsing fatigue lasting 6 months or longer. 2 Fatigue negatively impacts cancer survivors health-related quality of life, 3 daily function, and ability to work. 4 CF has mostly been studied among survivors of adulthood cancer. 5,6 Results from the few studies of adult survivors of childhood cancers including fatigue as a late effect are conflicting, reporting prevalences ranging from 11% to 30% In addition, only one study distinguished between acute and chronic fatigue, and compared the prevalence of CF among childhood cancer survivors to a control group from the general population. 10 Though unknown in detail, the etiology of cancer-related fatigue is viewed to be multifactorial and related to both biological and psychological factors. 1,11 Depression and psychological distress, insomnia, and chronic pain have been found to be associated with CF, but these conditions alone do not explain the prevalence of CF among cancer survivors. 1 Somatic late effects caused by cancer treatment add to the complexity. In survivors of adulthood Hodgkin lymphoma (HL), associations have been reported between CF and pulmonary dysfunction 12 and self-reported cardiac disease. 13 Studies among survivors of breast and testicular cancer indicate that CF might be associated with a low-grade 1 National Resource Center for Late Effects after Cancer Treatment, Department of Oncology, 2 Department of Paediatric Medicine, 3 Department of Cardiology, 4 Department of Respiratory Medicine, 5 Department of Behavioral Sciences in Medicine, Oslo University Hospital, Radiumhospitalet, Oslo, Norway. 6 Faculty of Medicine, University of Oslo, Oslo, Norway. 2
2 FATIGUE AFTER CHILDHOOD LEUKEMIA AND LYMPHOMA 3 inflammatory response, lected by increased levels of C-reactive protein (CRP) and selected cytokines Studying this possible relation may be of particular interest among survivors of lymphogenic malignancies, as B-symptoms (fever, night sweats, weight loss) at diagnosis are associated with increased levels of pro-inflammatory markers. 17 Further, B- symptoms at the time of diagnosis are positively related to CF among long-term HL survivors. 18,19 HL, non-hodgkin lymphoma (NHL), and acute lymphoblastic leukemia (ALL) represent 50% of all childhood cancers. Today s 5-year survival rates for these lymphogenic malignancies have reached 85% 95%. 20,21 The growing population of these survivors makes studies of late effects, including CF, increasingly important. We performed a cross-sectional study among adult survivors after childhood ALL, NHL, and HL (adult childhood leukemia/lymphoma survivors; CLSs) with the following aims: (1) to determine the prevalence of CF among the CLSs compared to controls from the general population, and (2) to explore factors associated with CF, including mental and somatic late effects and markers of low-grade inflammation. Based on the findings from HL survivors treated in adulthood, it was hypothesized that the prevalence of CF would be higher among CLSs than in the general population. In addition, the prevalence of CF in HL survivors was expected to be higher than among ALL and NHL survivors. We expected that mental and somatic late effects would be associated with CLSs report of CF. Furthermore, it was hypothesized that a low-grade inflammatory condition lected as elevated levels of CRP, leukocytes, and trombocytes would be associated with CF. Methods Patients and study design Eligible patients were identified by the Cancer Registry of Norway with the following eligibility criteria: (1) treatment for HL as their first cancer at university hospitals in Norway or treatment at Oslo University Hospital (OUH) for ALL or NHL; (2) diagnosed between 1970 and 2000 (1970 and 2002 for ALL due to later point of time of inclusion); (3) age at diagnosis p18 years (p16 years for ALL, as only pediatric patients were included) and survival for q5 years; (4) age at survey > 18 years; (5) alive as of June 2007 (April 2009 for ALL). For HL, the survey was national. Due to resource limitations, the survey was restricted to survivors of ALL and NHL from the South-Eastern Health Region of Norway, covering approximately 50% of the Norwegian population. Participants with a second cancer or ongoing pregnancy were excluded from all analyses concerning intergroup comparisons between HL, ALL, and NHL survivors. Such survivors were, however, included in analyses that compared survivors to controls, as the participants of the control group were unselected in terms of these conditions. From 2008 to 2011, eligible CLSs were invited to participate in a cross-sectional study on late effects. The survivors were invited to a general health check-up without specifically mentioning CF as a possible outcome. The study included a mailed questionnaire and a 2-day outpatient examination at OUH, which included a clinical examination, echocardiography, lung function tests, and fasting blood sampling. Levels of thyroid-stimulating hormone (TSH), thyroxin (T4), B-type natriuretic peptide (probnp), and CRP, and leukocyte and trombocyte counts were measured. The lowest detection level of CRP was 0.6 mg/l. A CRP level > 10 mg/l was considered to lect possible acute infections, and survivors with CRP levels > 10 mg/l (n = 14) were excluded from the analyses of the association between CF and inflammatory markers. They were, however, included in the other analyses, as the questionnaire had been filled in some weeks prior to the 2-day visit. The date of study was defined as the date of clinical examination (if present) or the date that the questionnaire was completed. Observation time was defined as the period from the date of diagnosis to the date of study. Information about prior treatment and clinical course was retrieved from medical records. The initial extent of the lymphomas were classified according to the Ann Arbor classification. 22 B-symptoms at diagnosis comprised a fever > 38 C and/or night sweats for more than 2 weeks preceding diagnosis and/or > 10% weight loss during the last 6 months. Treatment Treatment of ALL was predominantly based on chemotherapy alone and is described elsewhere. 23,24 Treatment for the lymphoma survivor participants has been previously summarized, 25 and in most cases included a combination of chemotherapy and radiotherapy, with large-field radiotherapy applied to patients with HL in the 1970s. Treatment periods were defined as before 1986 or later. Clinical findings Echocardiography was performed (GE Vivid 7 or E9; GE Vingmed, Horten, Norway) and analyzed following standard recommendations. 26 Aortic valve dysfunction (aortic valve stenosis and/or regurgitation) was identified by echocardiography using two-dimensional imaging. Doppler and color Doppler data were categorized as present when a survivor obtained a score of q2 on a four-grade scale (i.e., valvular dysfunction: 0 = normal, 1 = small, 2 = moderate, and 3 = severe). Left ventricular shortening fraction (SF)p28% defined reduced systolic function. ProBNPq20 pmol/l was considered to lect left ventricular dysfunction. Reduced cardiac function was defined as the presence of aortic valve dysfunction and/or SFp28% and/or probnpq20 pmol/l. Total lung capacity (TLC)p80% of predicted level was defined as lung volume reduction. Gas transfer impairment was defined as diffusion capacity of the lung for carbon monoxide (DLCO) of p80% of predicted level. Reduced lung function was defined as lung volume reduction and/or gas transfer impairment. TSH > 3.4 miu/l and/or T4 < 9.0 pmol/l was defined as unsubstituted ongoing hypothyroidism. Questionnaires The mailed questionnaire included the 11-item Chalder Fatigue Questionnaire (FQ), widely used for assessment of fatigue severity and for case detection in clinical and epidemiological studies. 27 Initial Likert scoring (0, 1, 2, 3) defines total fatigue (all 11 items) by simple addition with higher scores implying higher levels of fatigue. Two additional items ask for the duration and extent of fatigue. The scores (0, 1, 2, 3) are dichotomized (0, 0, 1, 1) for the definition of CF. CF is defined by a sum score of q4 for all 11 dichotomized items and a duration of q6 months. 27,28
3 4 HAMRE ET AL. Mental distress was assessed by the Hospital Anxiety and Depression Scale (HADS) consisting of 14 items 7 comprising the depression subscale and 7 comprising the anxiety subscale. Each item is scored from 0 (minimum) to 3 (maximum). The HADS total score is the sum scores for all 14 items. The questionnaire also asked for partnership status and highest level of education, dichotomized as p11 years and > 12 years. Controls Of 3254 subjects representative of the entire Norwegian population and previously included in a survey assessing CF in 1996, were between 19 and 50 years old and served as controls in the present study. Statistics Standard descriptive analyses were applied using SPSS version 18 with v 2 tests, t-tests, and Mann Whitney U tests analyzing differences between groups. The Pearson product moment correlation coefficient assessed correlations. Predictors of CF were evaluated by logistic regression analysis (odds ratios [OR] and 95% confidence intervals [CI]). Variables with a significance level of p < 0.1 in the univariate logistic regression analyses were included in the multivariate analyses. The significance level was set at pp0.05, two-sided. Age at survey, sex, educational level, and partnership status were adjusted for when the CLSs were compared to the controls. The ALL and the lymphoma samples differed in terms of ages at diagnosis and types of treatment and burden. Extent of disease was not categorized in ALL patients. When exploring effects of disease characteristics and treatment- and somatic late effects on CF, ALL and lymphoma survivors were analyzed separately, with NHL and HL survivors combined. Ethics The study was approved by Regional Committee for Medical Research Ethics. Results Patient characteristics Of 430 eligible survivors invited, 300 responded (70%). A total of 21 survivors were excluded (10 had incomplete questionnaires, 6 were pregnant, and 5 had a second cancer diagnosis), leaving 279 (65%) for studying the prevalence of CF. Of these, 246 attended the clinical examination. The 134 non-responders were more likely to be male (64%, p = 0.001) or lymphoma survivors (59%, p = 0.03), with no statistically significant differences as to age at diagnosis or age at survey or follow-up (data not shown). Further analysis of non-responders was not feasible due to restrictions from the ethical committee. Demographics of the CLSs and controls are summarized in Table 1. Disease characteristics and treatments of the CLSs are summarized in Table 2. The median age at diagnosis for the CLSs was 9.5 years (range = ), with a median observation time of 21.1 years (range = ). The median age at survey was 29.6 years (range = ) for the CLSs, compared to 34.0 years (range = ) among the controls ( p < 0.001). Compared to lymphoma survivors, ALL survivors were younger at both diagnosis and study ( p < 0.001) but with a longer observation time ( p = 0.005). Prevalence of CF among CLSs versus controls Twenty-eight percent of the CLSs had CF versus 8% of the controls ( p < 0.001; Table 3). When adjusting for sex and age at survey, the probability of having CF was 4.5 times higher among survivors compared with controls (OR = 4.5; 95% CI: ). This probability was highest among the HL survivors (OR = 5.9; 95% CI: ), followed by survivors of NHL (OR = 4.4; 95% CI: ) and ALL (OR = 3.6; 95% CI: ). Impaired heart function and reduced lung function were most frequently observed in HL survivors. Factors associated with CF among the CLSs Compared to ALL survivors, HL survivors displayed a significantly increased probability of reporting CF, but this was not observed in NHL survivors (Table 4). The chance of having CF increased with age at survey and with the HADS total score. Treatment period, sex, partnership status, and educational level did not influence CLSs probability of having CF. In the multivariate analysis, the elevated probability of having CF among HL survivors and the age-related association disappeared, with only the HADS total score remaining significantly associated with CF (OR = 1.15; 95% CI: ). Further sub-analyses separated ALL survivors from HL/ NHL survivors (Table 5). In multivariate analysis, ALL was the only group for which increasing age at survey was Table 1. Demographics for Childhood Leukemia/Lymphoma Survivors and Controls Total CLSs ALL NHL HL Controls N = 290 n = 151 n = 47 n = 92 N = 1405 p a Age at survey, years (range) 29.6 ( ) 28.0 ( ) 29.3 ( ) 35.0 ( ) 34.0 ( ) < Female 139 (50%) 78 (47%) 16 (65%) 45 (53%) 720 (51%) < Male 140 (50%) 70 (53%) 30 (36%) 40 (47%) 703 (49%) < Education > 12 years 175 (63%) 91 (62%) 22 (48%) 62 (73%) 1215 (85%) < In a partnership 145 (52%) 69 (47%) 24 (53%) 52 (61%) 929 (65%) < Age at diagnosis, years (range) 9.5 ( ) 4.8 ( ) 12.2 ( ) 14.6 ( ) Observation time, years (range) 21.1 ( ) 22.1 ( ) 18.4 ( ) 20.6 ( ) a CLSs versus controls. ALL, acute lymphoblastic leukemia; CLSs, childhood leukemia/lymphoma survivors; HL, Hodgkin lymphoma; NHL, non-hodgkin lymphoma.
4 FATIGUE AFTER CHILDHOOD LEUKEMIA AND LYMPHOMA 5 Table 2. Disease Characteristics, Treatment and Clinical Findings of Childhood Leukemia/Lymphoma Survivors Total ALL NHL HL Disease characteristics N = 279 n = 148 n = 46 n = 85 Stage I II NA 24 (52%) 60 (71%) Stage III IV NA 22 (48%) 25 (29%) B-symptoms a No NA 17 (37%) 58 (68%) Yes NA 11 (24%) 18 (21%) Unknown NA 18 (38%) 9 (11%) Treatment N = 279 n = 148 n = 46 n = 85 Radiotherapy only 13 (5%) 0 1 (2%) 12 (14%) Chemotherapy only 179 (64%) 132 (89%) 27 (59%) 20 (23%) Radiotherapy + chemotherapy 87 (31%) 16 (11%) 18 (39%) 53 (62%) Radiotherapy, CNS 19 (7%) 16 b (11%) 3 (7%) 0 Dose (Gy, median [range]) c 20 (12 54) 20 (12 25) (24 54) Radiotherapy, mediastinum 69 (25%) 0 7 (15%) 62 (73%) Dose (Gy, median [range]) c 36 (18 44) 40 (22 40) 36 (18 44) Radiotherapy, other 12 (4%) 0 9 d (20%) 3 (4%) Dose (Gy, median [range]) c 40 (13 41) 27 ( ) 40 ( ) AC 199 (71%) 104 (70%) 42 (91%) 53 (62%) Dose (mg/m 2, median [range]) c 150 (40 510) 120 (40 510) 150 (50 460) 160 (50 401) HDT 12 (4%) 3 (2%) 5 (11%) 4 (5%) Relapse 25 (9%) 18 (12%) 3 (7%) 4 (5%) Clinical findings e N = 246 e n = 130 e n = 42 e n = 74 e Impaired heart function 73 (28%) 35 (27%) 5 (12%) 33 (45%) Reduced SF 55 (22%) 33 (25%) 5 (12%) 17 (23%) ProBNP q20 pmol/l 21 (9%) 4 (3%) 1 (2%) 16 (22%) Aortic valve dysfunction 16 (7%) (22%) Reduced lung function 70 (28%) 35 (27%) 10 (24%) 25 (34%) Lung volume reduction 19 (8%) 7 (5%) 3 (7%) 9 (12%) Impaired gas transfer 60 (24%) 33 (25%) 7 (17%) 20 (27%) BMI > 30 kg/m 2 31 (12%) 22 (17%) 4 (10%) 5 (7%) Present hypothyroidism 49 f (20%) 16 (12%) 5 (12%) 28 (38%) HADS total score g (mean SD) a Includes night sweats, fever of unknown cause, and weight loss at time of diagnosis. b Including nine irradiated to medulla spinalis. c Per patient receiving the treatment. d Including five with total body irradiation. e 33 patients did not perform a clinical examination (questionnaire only). f 48 had elevated TSH only; one had elevated T4 and TSH. g Based on questionnaire: N = 279; n ALL = 148, n NHL = 46, n HL = 85. ALL, acute lymphoblastic leukemia; AC, anthracycline; BMI, body mass index; CNS, central nervous system; HADS, Hospital Anxiety and Depression Scale; HDT, high-dose chemotherapy with stem cell support; HL, Hodgkin lymphoma; NA, not applicable; NHL, non-hodgkin lymphoma; probnp, B-type natriuretic peptide; SD, standard deviation; SF, shortening fraction of left ventricle; T4, thyroxin; TSH, thyroidstimulating hormone. Table 3. Chronic Fatigue Among Childhood Leukemia/Lymphoma Survivors (N = 290) and Controls (N = 1405) Crude Adjusted a CF/total (%) OR (95% CI) p OR (95% CI) p Controls 118/1405 (8%) CLSs 79/290 (28%) 4.2 ( ) < ( ) < Controls 118/1405 (8%) CLS type: ALL 34/151 (23%) 3.2 ( ) < ( ) < NHL 14/47 (30%) 4.6 ( ) < ( ) < HL 32/92 (35%) 5.8 ( ) < ( ) < Note: CF defined as a Chalder Fatigue Questionnaire sum score of q4 for all 11 dichotomized items and a duration of q6 months. a Adjusted for age at survey, sex, education, and partnership status. ALL, acute lymphoblastic leukemia; CI, confidence interval; CF, chronic fatigue; CLSs, childhood leukemia/lymphoma survivors; HL, Hodgkin lymphoma; NHL, non-hodgkin lymphoma; OR, odds ratio;, erence.
5 6 HAMRE ET AL. Table 4. Risk of Chronic Fatigue Among Childhood Leukemia/Lymphoma Survivors (N = 279) Related to Diagnosis, Demographic Factors, BMI, Thyroid Function, and HADS Univariate Multivariate OR (95% CI) p OR (95% CI) p ALL NHL 1.4 ( ) ( ) 0.4 HL 1.8 ( ) ( ) 0.2 Age at survey 1.04 ( ) ( ) 0.1 Treatment after 1985 Treatment ( ) ( ) 0.7 Male Female 0.9 ( ) ( ) 0.6 In a partnership Not in a partnership Educationq12 years Education p11 years 1.6 ( ) 0.1 BMI < 30 kg/m 2 BMIq30 kg/m ( ) 0.1 Thyroid status normal Present hypothyroidism 1.8 ( ) ( ) 0.4 HADS total score 1.1 ( ) < ( ) < Note: CF defined as a Chalder Fatigue Questionnaire sum score q4 for all 11 dichotomized items and a duration of q6 months. Only variables with significance level of p < 0.1 in the univariate logistic regression analyses were included in the multivariate analyses. ALL, acute lymphoblastic leukemia; BMI, body mass index; CI, confidence interval; CLSs, childhood leukemia/lymphoma survivors; CF, chronic fatigue; HADS, Hospital Anxiety and Depression Scale; HL, Hodgkin lymphoma; NHL, non-hodgkin lymphoma; OR, odds ratio;, erence. associated with increased probability of reporting CF (OR = 1.1; 95% CI: ). No significant associations were found between CF and treatment period, sex, relapse, radiotherapy, cumulative dose of anthracycline, reduced cardiac function, or reduced lung function in either of the diagnostic groups. The presence of B-symptoms in lymphoma survivors was significantly associated with increased probability of CF (OR = 2.5; 95% CI: ). The Pearson product moment correlation coefficient between the total fatigue score and the HADS score was Leukocyte, neutrophil, and trombocyte counts were significantly higher among survivors with CF compared to those without CF (Table 6), though with minimal numeric differences between CLSs with or without CF, these variables were not included in the regression analyses. Discussion In this population-based study of adult CLSs with a median observation time of 20 years, the prevalence of CF was 3.5 times higher than in the general population. Higher age at survey was associated with CF among the ALL survivors, whereas the presence of B-symptoms at diagnosis increased the probability of CF among the lymphoma survivors. Leukocyte, neutrophil, and trombocyte counts were significantly higher among CLSs with CF compared to those without. Neither previous cancer treatment nor somatic clinical findings impacted the probability of having CF. In spite of the relatively young age at survey (median = 29.6 years) and a very long follow-up time (median = 21.1 years), the prevalence of CF among CLSs (all diagnoses included) in this study was as high as previously reported among survivors of adult HL. 28 To our surprise, the prevalence of CF was not lower among the ALL survivors compared to the lymphoma survivors after adjusting for age, sex, and treatment period. Three other studies have explored fatigue in adult survivors of childhood ALL and lymphoma, all with comparable observation times (14 23 years). 7 9 Meeske et al. reported a 30% prevalence of fatigue in survivors of childhood ALL, but the response rate was low (44%) and no control group was included. 8 Mulrooney et al. found a prevalence of 15% in ALL survivors compared to 10% in sibling controls. This study also demonstrated a prevalence of 21% in childhood HL survivors. 7 Langeveld et al. were unable to demonstrate an increased risk of fatigue for either childhood ALL or NHL survivors compared to acontrolgroup, 9 though the validity of the instrument used in that study (the Multidimensional Fatigue Inventory [MFI-20]) has been questioned for use among cancer patients. 30 Further, direct comparisons across these studies and ours are hampered by the use of four different instruments for assessment of fatigue (Piper Fatigue Scale, Functional Assessment of Chronic Illness Therapy-Fatigue [FACIT-F], MFI-20, and FQ). Furthermore, the three latter studies assessed acute fatigue at time of survey while we, on the contrary, have integrated a duration of at least 6 months in our definition of CF. Jóhannsdóttir et al. reported a prevalence of CF after childhood cancer almost double that of the Norwegian general population (11% versus 6%), 10 but the study consisted of survivors of rare types of pediatric cancers (acute myeloid leukemia, infratentorial astrocytoma, and Wilms tumor) and had a relatively young median age at survey (24 years). A study of adult HL survivors found an association between impaired DLCO and CF, but applied a somewhat stricter definition of reduced lung function (DLCO p75% of predicted compared to p80% in the present study). 12 Mulrooney et al. s much larger study sample of questionnaires
6 FATIGUE AFTER CHILDHOOD LEUKEMIA AND LYMPHOMA 7 Table 5. Risk for Chronic Fatigue Related to Disease Characteristics, Treatment Factors, and Heart and Lung Function for Survivors of Childhood Acute Lymphoblastic Leukemia and Lymphoma Univariate Multivariate OR (95% CI) p OR (95% CI) p ALL (n = 148) Age at survey 1.0 ( ) ( ) 0.01 Treatment after 1985 Treatment ( ) ( ) 0.4 Male Female 0.8 ( ) ( ) 0.8 No relapse Relapse 0.7 ( ) 0.5 AC, cumulative dose 1.0 ( ) 0.9 No RT RT CNS 1.2 ( ) 0.8 Normal heart function Reduced heart function 1.7 ( ) 0.2 Normal lung function Reduced lung function 1.0 ( ) 0.8 Lymphoma (n = 131) Age at survey 1.0 ( ) ( ) 0.5 Treatment Treatment after ( ) ( ) 0.5 Male Female 1.1 ( ) ( ) 0.9 No relapse Relapse 0.8 ( ) 0.8 Stage I II Stage III IV 1.4 ( ) 0.4 B-symptoms a No Yes 2.4 ( ) ( ) 0.05 Unknown 0.9 ( ) ( ) 0.9 AC, cumulative dose 1.0 ( ) 0.8 No RT or Other RT mediastinum 1.0 ( ) 0.9 Normal heart function Reduced heart function 1.6 ( ) 0.2 Normal lung function Reduced lung function 1.2 ( ) 0.7 Note: CF defined as a Chalder Fatigue Questionnaire sum score of q4 for all 11 dichotomized items and a duration of q6 months. Only variables with significance level p < 0.1 in the univariate logistic regression analyses were included in the multivariate analyses. a Includes night sweats, fever of unknown cause, and weight loss at time of diagnosis. ALL, acute lymphoblastic leukemia; AC, anthracycline; CI, confidence interval; CF, chronic fatigue; CNS, central nervous system; OR, odds ratio;, erence; RT, radiotherapy. from 2600 adult childhood cancer survivors demonstrated an association between fatigue and pulmonary fibrosis, and also between fatigue and congestive heart failure. 7 In the present study, no associations emerged between CF and reduced lung or heart function. However, the findings in Mulrooney et al. s study were based on patients reports of these late effects, whereas we assessed heart and pulmonary functions by objective tests. One explanation for the lack of associations between somatic late effects and CF in our study may be that the assessed cardiac and pulmonary findings generally were at a Table 6. Inflammatory Markers Related to Chronic Fatigue in Childhood Leukemia/Lymphoma Survivors (N = 230 a ) No CF (n = 164) CF (n = 66) p CRP (mg/l) (median [range]) 1.0 (< ) 1.0 (< ) 0.9 b Leukocytes ( 10 9 ) (mean SD) c Neutrophils ( 10 9 ) (mean SD) c Lymphocytes ( 10 9 ) (mean SD) c Trombocytes ( 10 9 ) (mean SD) c Note: CF defined as a Chalder Fatigue Questionnaire sum score of q4 for all 11 dichotomized items and a duration of q6 months. a Two out-clinic patients missed blood tests; 14 patients excluded due to CRP > 10 mg/l. b Mann Whitney U test. c t-test. CF, chronic fatigue; CLSs, childhood leukemia/lymphoma survivors; CRP, C-reactive protein; SD, standard deviation.
7 8 HAMRE ET AL. subclinical state and thus probably not symptomatic at the time of study. The association between fatigue and psychological distress is well documented. 1,31 The Pearson product moment correlation coefficient between the total fatigue score and the HADS total score in our material was 0.54, confirming the expected moderate correlation between the two scales. Among the ALL survivors, age was the only factor associated with CF. This result was not observed in the lymphoma group consisting of somewhat older participants. However, among survivors aged > 30 years at survey, the prevalence was similar in all survivors (ALL 34% versus lymphoma 30%, p = 0.6). The question is open as to whether at least some CLSs are particularly susceptible to the physiological age-dependent increase of CF. In the general population, the prevalence of fatigue has been demonstrated to increase with age. 32 Still, the present sample s size limits the possibility of drawing firm conclusions as to differences in CF s relation to age. As demonstrated previously among adult HL survivors, 28 lymphoma survivors in this study that presented with B- symptoms at diagnosis had an elevated probability of having CF, although the groups were small, with the risk of type I error. As B-symptoms at diagnosis are associated with an increase in inflammatory markers, 17 our finding supports the hypothesis that the inflammatory system may be involved in the mechanism of CF, at least after malignant lymphoma. The significantly (though minimally) elevated blood cell counts among the survivors with CF as compared to those without CF seem to support our hypothesis, and these serological findings are in concordance with other studies Our population-based study, including a control group from the Norwegian general population, studied the impact of objectively assessed late effects upon CF. A response rate of 70% must be considered high in this patient population with a follow-up period of 20 years. 33 Whether survivors with CF are overrepresented or underrepresented in our study cannot be determined. A previous study of survivors of adult HL suggested that non-participants displayed more comorbidity than participants. Hence, more non-participants may suffer from fatigue, which possibly limits their survey participation. 34 The heterogeneity between the three diagnostic groups (in terms of treatment burden and modalities, and different ages at diagnosis) implied that disease characteristics and treatmentrelated variables had to be analyzed by diagnostic subgroups. Small group sizes may have limited the interpretation of the intergroup differences, thereby also increasing the risk of type II errors. Finally, this study primarily dealt with the relationship between CF and survivors somatic health status, but it should be noted that other conditions such as pain, sleep disturbances, and physical inactivity have also shown associations with cancer-related fatigue. 7,35 Conclusion We found a 28% prevalence of CF among adult CLSs as compared to 8% in controls. The etiology of CF remains unclear; in our study, objectively measured subclinical cardiac and pulmonary sequelae after cancer treatment were not associated with CF. The association between and CF and selected inflammatory markers lends some support to the hypothesis that a low-grade inflammatory response may be involved in the pathogenesis of CF in CLSs. Acknowledgments We are thankful for practical help from Siri L. Hess. Eva Widing, Unni Blom, Svein Kolmannsskog, Trond Flægstad, and Geir Tjønnfjord were helpful in the eligibility process. Richard Massey performed the echocardiograms. This work was supported by Helse Sørøst HF. Disclaimer Results from this study were previously presented at the 2011 European Symposium on Late Complications after Childhood Cancer Author Disclosure Statement No competing financial interests exist. References 1. Stone PC, Minton O. Cancer-related fatigue. Eur J Cancer. 2008;44(8): Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med. 1994;121(12): Hjermstad MJ, Oldervoll L, Fossa SD, et al. Quality of life in long-term Hodgkin s disease survivors with chronic fatigue. Eur J Cancer. 2006;42(3): Spelten ER, Verbeek JH, Uitterhoeve AL, et al. Cancer, fatigue and the return of patients to work-a prospective cohort study. Eur J Cancer. 2003;39(11): Ganz PA, Bower JE. Cancer related fatigue: a focus on breast cancer and Hodgkin s disease survivors. Acta Oncol. 2007; 46(4): Orre IJ, Fossa SD, Murison R, et al. Chronic cancer-related fatigue in long-term survivors of testicular cancer. J Psychosom Res. 2008;64(4): Mulrooney DA, Ness KK, Neglia JP, et al. Fatigue and sleep disturbance in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study (CCSS). Sleep. 2008;31(2): Meeske KA, Siegel SE, Globe DR, et al. Prevalence and correlates of fatigue in long-term survivors of childhood leukemia. J Clin Oncol. 2005;23(24): Langeveld NE, Grootenhuis MA, Voute PA, et al. No excess fatigue in young adult survivors of childhood cancer. Eur J Cancer. 2003;39(2): Jóhannsdóttir IM, Hjermstad MJ, Moum T, et al. Increased prevalence of chronic fatigue among survivors of childhood cancers: a population-based study. Pediatr Blood Cancer. 2012;58(3): Prue G, Rankin J, Allen J, et al. Cancer-related fatigue: a critical appraisal. Eur J Cancer. 2006;42(7): Knobel H, Havard LJ, Brit LM, et al. Late medical complications and fatigue in Hodgkin s disease survivors. J Clin Oncol. 2001;19(13): Ng AK, Li S, Recklitis C, et al. A comparison between longterm survivors of Hodgkin s disease and their siblings on fatigue level and factors predicting for increased fatigue. Ann Oncol. 2005;16(12): Orre IJ, Murison R, Dahl AA, et al. Levels of circulating interleukin-1 receptor antagonist and C-reactive protein in long-term survivors of testicular cancer with chronic cancer-related fatigue. Brain Behav Immun. 2009;23(6):
8 FATIGUE AFTER CHILDHOOD LEUKEMIA AND LYMPHOMA Bower JE. Cancer-related fatigue: links with inflammation in cancer patients and survivors. Brain Behav Immun. 2007; 21(7): Alexander S, Minton O, Andrews P, et al. A comparison of the characteristics of disease-free breast cancer survivors with or without cancer-related fatigue syndrome. Eur J Cancer. 2009;45(3): Seymour JF, Talpaz M, Cabanillas F, et al. Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol. 1995;13(3): Hjermstad MJ, Fossa SD, Oldervoll L, et al. Fatigue in longterm Hodgkin s Disease survivors: a follow-up study. J Clin Oncol. 2005;23(27): Ruffer JU, Flechtner H, Tralls P, et al. Fatigue in long-term survivors of Hodgkin s lymphoma: a report from the German Hodgkin Lymphoma Study Group (GHSG). Eur J Cancer. 2003;39(15): Kaatsch P. Epidemiology of childhood cancer. Cancer Treat Rev. 2010;36(4): Gatta G, Corazziari I, Magnani C, et al. Childhood cancer survival in Europe. Ann Oncol. 2003;14(Suppl 5): v Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin s disease: Cotswolds meeting. J Clin Oncol. 1989;7(11): Moe PJ, Seip M, Finne PH. Intermediate dose methotrexate (IDM) in childhood acute lymphocytic leukemia in Norway. Preliminary results of a national treatment program. Acta Paediatr Scand. 1981;70(1): Gustafsson G, Schmiegelow K, Forestier E, et al. Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO). Leukemia. 2000; 14(12): Hamre H, Kiserud CE, Ruud E, et al. Gonadal function and parenthood 20 years after treatment for childhood lymphoma: a cross-sectional study. Pediatr Blood Cancer. 2012; 59(2): Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification. J Am Soc Echocardiogr. 2005; 18(12): Chalder T, Berelowitz G, Pawlikowska T, et al. Development of a fatigue scale. J Psychosom Res. 1993;37(2): Loge JH, Abrahamsen AF, Ekeberg O, Kaasa S. Hodgkin s disease survivors more fatigued than the general population. J Clin Oncol. 1999;17(1): Loge JH, Ekeberg O, Kaasa S. Fatigue in the general Norwegian population: normative data and associations. J Psychosom Res. 1998;45(1): Minton O, Stone P. A systematic review of the scales used for the measurement of cancer-related fatigue (CRF). Ann Oncol. 2009;20(1): Loge JH, Abrahamsen AF, Ekeberg, Kaasa S. Fatigue and psychiatric morbidity among Hodgkin s disease survivors. J Pain Symptom Manage. 2000;19(2): Schwarz R, Krauss O, Hinz A. Fatigue in the general population. Onkologie. 2003;26(2): Asch DA, Jedrziewski MK, Christakis NA. Response rates to mail surveys published in medical journals. J Clin Epidemiol. 1997;50(10): Kiserud CE, Loge JH, Fossa A, et al. Mortality is persistently increased in Hodgkin s lymphoma survivors. Eur J Cancer. 2010;46(9): Berger AM, Gerber LH, Mayer DK. Cancer-related fatigue: implications for breast cancer survivors. Cancer. 2012;118(8 Suppl): Zeller B, Hamre H, Kanelloupolos A, et al. High prevalence of chronic fatigue in long term survivors of childhood acute lymphoblastic leukemia and lymphoma. A population based study. Abstract presented at European Symposium on Late Complications After Childhood Cancer, Amsterdam, The Netherlands. September 29 30, Address correspondence to: Hanne Hamre, MD Department of Oncology National Resource Center for Late Effects after Cancer Treatment Oslo University Hospital Postboks 4953 Nydalen, 0424 Oslo Norway hannh@ous-hf.no
Predictors and course of chronic fatigue in long-term breast cancer survivors
J Cancer Surviv (2010) 4:405 414 DOI 10.1007/s11764-010-0145-7 Predictors and course of chronic fatigue in long-term breast cancer survivors Kristin Valborg Reinertsen & Milada Cvancarova & Jon H. Loge
More informationISSN: X (Print) X (Online) Journal homepage:
Acta Oncologica ISSN: 0284-186X (Print) 1651-226X (Online) Journal homepage: https://www.tandfonline.com/loi/ionc20 Perceived needs for different components in a rehabilitation program among cancer survivors
More informationChronic fatigue in 812 testicular cancer survivors during longterm follow up: increasing prevalence and risk factors
Annals of Oncology Advance Access published August 11, 2015 1 Chronic fatigue in 812 testicular cancer survivors during longterm follow up: increasing prevalence and risk factors M. Sprauten 1, H. S. Haugnes
More information1. Study Title. Exercise and Late Mortality in 5-Year Survivors of Childhood Cancer: a Report from the Childhood Cancer Survivor Study.
CCSS Analysis Concept Proposal Exercise, Mortality, & Childhood Cancer 1 1. Study Title. Exercise and Late Mortality in 5-Year Survivors of Childhood Cancer: a Report from the Childhood Cancer Survivor
More informationCHILDHOOD CANCER SURVIVOR STUDY ANALYSIS CONCEPT PROPOSAL
CHILDHOOD CANCER SURVIVOR STUDY ANALYSIS CONCEPT PROPOSAL 1. Study title: Subsequent neoplasms among survivors of childhood cancer not previously treated with radiation 2. Working group and investigators:
More informationCHILDHOOD CANCER SURVIVAL STUDY CONCEPT PROPOSAL
Version: March 3, 2006 CHILDHOOD CANCER SURVIVAL STUDY CONCEPT PROPOSAL I- Title: Neurocognitive and Psychosocial Correlates of Adaptive Functioning in Survivors of Childhood Leukemia and Lymphoma. II-
More informationChanges Over Time in Occurrence, Severity, and Distress of Common Symptoms During and After Radiation Therapy for Breast Cancer
98 Journal of Pain and Symptom Management Vol. 45 No. June Original Article Changes Over Time in Occurrence, Severity, and Distress of Common Symptoms During and After Radiation Therapy for Breast Cancer
More informationPsychosocial Outcomes and Health-Related Quality of Life in Adult Childhood Cancer Survivors: A Report from the Childhood Cancer Survivor Study
435 Psychosocial Outcomes and Health-Related Quality of Life in Adult Childhood Cancer Survivors: A Report from the Childhood Cancer Survivor Study Lonnie K. Zeltzer, 1 Qian Lu, 1 Wendy Leisenring, 3 Jennie
More informationSecond Neoplasms Working Group. CCSS Investigators Meeting June 2017
Second Neoplasms Working Group CCSS Investigators Meeting June 2017 Second Neoplasms Working Group Overview Ongoing review, adjudication and entry of reported neoplasms into data set Initial review of
More informationCancer patients needs for rehabilitation services
Acta Oncologica ISSN: 0284-186X (Print) 1651-226X (Online) Journal homepage: http://www.tandfonline.com/loi/ionc20 Cancer patients needs for rehabilitation services Lene Thorsen, Gunhild M. Gjerset, Jon
More informationExercise Behavior & Major Cardiac Events: CCSS 1 STUDY TITLE
STUDY TITLE Exercise Behavior & Major Cardiac Events: CCSS 1 Association Between Exercise Behavior and Incidence of Major Cardiac Events in Adult Survivors of Childhood Cancer: A Report from the Childhood
More informationdiagnosis and initial treatment at one of the 27 collaborating CCSS institutions;
Peer-delivered smoking counseling for childhood cancer survivors increases rate of cessation: the Partnership for Health Study Emmons K M, Puleo E, Park E, Gritz E R, Butterfield R M, Weeks J C, Mertens
More informationWhy? What? When? How? Dr C Fryer FRCPC) Surveillance
Why? What? When? How? Dr C Fryer FRCPC) Surveillance 1 Disclosure; Disclosure; None. I have no conflicts. I have no industry financial relationships. Background: Relapse is the single most likely late
More information3. BACKGROUND AND RATIONALE
CHILDHOOD CANCER SURVIVOR STUDY Revised Analysis Concept Proposal 10-17 October 12, 2011 1. STUDY TITLE: Growth Hormone Exposure as a risk factor for the development of Subsequent Central Nervous System
More informationLate Effects in Pediatric Cancer Survivors
Late Effects in Pediatric Cancer Survivors LISA K OPP, DO ASSOCIATE PROFESSOR THE UNIVERSITY OF ARIZONA DEPARTMENT OF PEDIATRICS DIVISION OF HEMATOLOGY/ONCOLOGY/BMT Objectives Review Childhood Cancer and
More informationa) Study Title: The impact of chronic disease on health care utilization in the CCSS cohort
Analysis Concept Proposal a) Study Title: The impact of chronic disease on health care utilization in the CCSS cohort b) Working Group Investigators This proposed project will be developed through the
More informationCCSS Concept Proposal Working Group: Biostatistics and Epidemiology
Draft date: June 26, 2010 CCSS Concept Proposal Working Group: Biostatistics and Epidemiology Title: Conditional Survival in Pediatric Malignancies: A Comparison of CCSS and SEER Data Proposed Investigators:
More informationBreast Cancer in Childhood Cancer Survivors: The Impact of Screening on Morbidity
Breast Cancer in Childhood Cancer Survivors: The Impact of Screening on Morbidity WORKING GROUP: This report will be written within the Cancer Control Working Group with oversight from the Second Malignant
More informationEvidence tables from the systematic literature search for premature ovarian insufficiency surveillance in female CAYA cancer survivors.
Evidence tables from the systematic literature search for premature ovarian insufficiency surveillance in female CAYA cancer survivors. Who needs surveillance? Chiarelli et al. Early menopause and Infertility
More informationThe Current Pediatric Oncology Landscape
The Current Pediatric Oncology Landscape An Imperative for Change Smita Bhatia, MD, MPH UAB Department of Pediatrics at Children s Hospital of Alabama Five-year Observed Survival Rates for Two Time Periods,
More informationCHILDHOOD CANCER SURVIVOR STUDY Long-Term Morbidity in Survivors of Childhood Leukemia with Down Syndrome Analysis Concept Proposal
CHILDHOOD CANCER SURVIVOR STUDY Long-Term Morbidity in of Childhood Leukemia with Down Syndrome Analysis Concept Proposal Working Group and Investigators Genetics Working Group & Chronic Disease Working
More informationThe Relationship Between Cancer-Related Fatigue and Patient Satisfaction with Quality of Life in Cancer
40 Journal of Pain and Symptom Management Vol. 34 No. 1 July 2007 Original Article The Relationship Between Cancer-Related Fatigue and Patient Satisfaction with Quality of Life in Cancer Digant Gupta,
More informationPediatric Oncology. Vlad Radulescu, MD
Pediatric Oncology Vlad Radulescu, MD Objectives Review the epidemiology of childhood cancer Discuss the presenting signs and symptoms, general treatment principles and overall prognosis of the most common
More informationLate complications after hematopoietic stem cell transplant in adult patients
Late complications after hematopoietic stem cell transplant in adult patients Gérard Socié, MD, PhD Hematology/Transplantation, Hospital Saint Louis, Paris, France Synopsis H S C T Allogeneic HSCT activity
More informationQuality of End-of-Life Care in Patients with Hematologic Malignancies: A Retrospective Cohort Study
Quality of End-of-Life Care in Patients with Hematologic Malignancies: A Retrospective Cohort Study David Hui, Neha Didwaniya, Marieberta Vidal, Seong Hoon Shin, Gary Chisholm, Joyce Roquemore, Eduardo
More informationMedical Late Effects of Childhood Cancer
Medical Late Effects of Childhood Cancer Robert Goldsby Associate Professor of Clinical Pediatric UCSF Late Mortality in 5+ Year Survivors 1.00 US Female US Male Survival function estimate 0.70 0.75 0.80
More informationClinical material and methods. Departments of 1 Cardiology and 2 Anatomy, Gaziantep University, School of Medicine, Gaziantep, Turkey
Interatrial Block and P-Terminal Force: A Reflection of Mitral Stenosis Severity on Electrocardiography Murat Yuce 1, Vedat Davutoglu 1, Cayan Akkoyun 1, Nese Kizilkan 2, Suleyman Ercan 1, Murat Akcay
More informationCitation for published version (APA): van Dijk, I. W. E. M. (2014). Radiation-associated adverse events after childhood cancer
UvA-DARE (Digital Academic Repository) Radiation-associated adverse events after childhood cancer van Dijk, Irma Link to publication Citation for published version (APA): van Dijk, I. W. E. M. (14). Radiation-associated
More informationPrevention and screening of long term side effects. Lena Specht MD DMSc Professor of Oncology Rigshospitalet, University of Copenhagen Denmark
Prevention and screening of long term side effects Lena Specht MD DMSc Professor of Oncology Rigshospitalet, University of Copenhagen Denmark Disclosures Member of Advisory Board and Principal Investigator,
More informationCHILDHOOD CANER SURVIVOR STUDY ANALYSIS CONCEPT PROPOSAL
CHILDHOOD CANER SURVIVOR STUDY ANALYSIS CONCEPT PROPOSAL Project Title: Comparison of risks of mortality (all-cause, cause-specific) and invasive second or subsequent cancers: a Childhood Cancer Survivor
More informationFatigue and Psychiatric Morbidity Among Hodgkin s Disease Survivors
Vol. 19 No. 2 February 2000 Journal of Pain and Symptom Management 91 Original Article Fatigue and Psychiatric Morbidity Among Hodgkin s Disease Survivors Jon Håvard Loge, MD, Arne Foss Abrahamsen, MD,
More informationLong term toxicity of treatment. Laurence Brugieres Children and Adolescent Oncologic department
Long term toxicity of treatment Laurence Brugieres Children and Adolescent Oncologic department Most TYA with cancer are cured from their malignancy TRAMA 2016 2 What are the consequences of cancer treatment?
More informationSURVIVORSHIP WITH LYMPHOMA APRIL SHAMY MD,CM JEWISH GENERAL HOSPITAL MCGILL UNIVERSITY
SURVIVORSHIP WITH LYMPHOMA APRIL SHAMY MD,CM JEWISH GENERAL HOSPITAL MCGILL UNIVERSITY Some Statistics Approximately 1 in 2 Canadians develop cancer 25% of Canadians die of cancer 2009: 810,000 Canadians
More informationIdentifying Geographic & Socioeconomic Disparities in Access to Care for Pediatric Cancer Patients in Texas
Identifying Geographic & Socioeconomic Disparities in Access to Care for Pediatric Cancer Patients in Texas Mary T. Austin, MD, MPH Assistant Professor, Pediatric Surgery University of Texas Health Science
More informationTitle: Incidence of chronic disease among childhood cancer survivors by treatment era and temporal trends in treatment exposure
Childhood Cancer Survivor Study Analysis Concept Proposal Title: Incidence of chronic disease among childhood cancer survivors by treatment era and temporal trends in treatment exposure Working Group &
More informationTitle: Characterization of drinking in childhood cancer survivors compared to general population
Title: Characterization of drinking in childhood cancer survivors compared to general population Working Group and Investigators: Anne Lown, Rob Goldsby, and Dan Dohan Background and Rationale: During
More informationChildhood Cancer Survivor Study Study Proposal: Male Health Questionnaire (MHQ) and CED February 2015
Childhood Cancer Survivor Study Study Proposal: Male Health Questionnaire (MHQ) and CED February 2015 1. STUDY TITLE: Cyclophosphamide Equivalent Dosing and Male Health Late Effects Infertility, Erectile
More informationChildhood Cancer Survivor Study Analysis Concept Proposal
Childhood Cancer Survivor Study Analysis Concept Proposal Title: Long-Term Outcomes of Childhood Central Nervous System Tumor Survivors: A Report from the Childhood Cancer Survivor Study Working Group
More informationLymphoma: What You Need to Know. Richard van der Jagt MD, FRCPC
Lymphoma: What You Need to Know Richard van der Jagt MD, FRCPC Overview Concepts, classification, biology Epidemiology Clinical presentation Diagnosis Staging Three important types of lymphoma Conceptualizing
More informationPEDIATRIC & ADOLESCENT CANCER SURVIVORSHIP. Denise Rokitka, MD, MPH
PEDIATRIC & ADOLESCENT CANCER SURVIVORSHIP Denise Rokitka, MD, MPH Objectives Describe incidence of childhood cancer and survival rates and causes of early mortality. Understand the late effects of cancer
More informationAssessing quality of life in sarkoma trials
Pan-European Clinical Trials under current EU regulations: A training course for data managers, study nurses, and junior clinical investigators London, January 24/25, 2008 Assessing quality of life in
More informationFatigue in Long-Term Breast Carcinoma Survivors. BACKGROUND. A longitudinal study was designed to evaluate the prevalence, persistence,
751 Fatigue in Long-Term Breast Carcinoma Survivors A Longitudinal Investigation Julienne E. Bower, Ph.D. 1 3 Patricia A. Ganz, M.D. 3 5 Katherine A. Desmond, M.S. 6 Coen Bernaards, Ph.D. 7 Julia H. Rowland,
More informationLate effects after treatment for malignant lymphoma. Cecilie Essholt Kiserud, MD
Late effects after treatment for malignant lymphoma Cecilie Essholt Kiserud, MD Department of Clinical Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Faculty of Medicine, University
More informationInflammation in Adolescence and Schizophrenia Risk in Adulthood By Brian Miller, MD, PhD, MPH
Inflammation in Adolescence and Schizophrenia Risk in Adulthood By Brian Miller, MD, PhD, MPH 2016 Psychiatric Times RESEARCH UPDATE The investigation of immune system abnormalities in schizophrenia, though
More informationPERFORMANCE AFTER HSCT Mutlu arat, md ıstanbul bilim un., dept. hematology ıstanbul, turkey
PERFORMANCE AFTER HSCT Mutlu arat, md ıstanbul bilim un., dept. hematology ıstanbul, turkey Joint Educational Meeting of the EBMT Severe Aplastic Anaemia, Late Effects and Autoimmune Diseases Working Parties
More information282 Journal of Pain and Symptom Management Vol. 46 No. 2 August 2013
282 Journal of Pain and Symptom Management Vol. 46 No. 2 August 2013 Brief Report Comparing the Retrospective Reports of Fatigue Using the Fatigue Symptom Index With Daily Diary Ratings in Women Receiving
More informationLong-term risk of second malignancy after treatment of Hodgkin s disease: the influence of treatment, age and follow-up time
Original article Annals of Oncology 13: 1786 1791, 2002 DOI: 10.1093/annonc/mdf289 Long-term risk of second malignancy after treatment of Hodgkin s disease: the influence of treatment, age and follow-up
More informationHealth-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma
British Journal of Haematology, 1997, 97, 29 37 Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma FINN WISLØFF 1 AND MARTIN HJORTH 2 for the
More informationCCSS Neurology Committee Report: 6/08
Neurology Committee Report: 6/08 Roger J. Packer, MD Executive Director Neuroscience and Behavioral Medicine Chairman, Neurology Director, Brain Tumor Institute Children s s National Medical Center Washington,
More informationDisclosures. This presentation is the intellectual property of the author. Contact them for permission to reprint and/or distribute.
ALL in AYAs: Health Outcomes as a Criterion for Selecting Optimal Therapy David R. Freyer, DO, MS Director, Survivorship and Supportive Care Program, Children s Center for Cancer and Blood Diseases, Children
More informationMultidimensional fatigue and its correlates in hospitalized advanced cancer patients
Chapter 5 Multidimensional fatigue and its correlates in hospitalized advanced cancer patients Michael Echtelda,b Saskia Teunissenc Jan Passchierb Susanne Claessena, Ronald de Wita Karin van der Rijta
More informationMatthew J. Ehrhardt John T. Sandlund
CCSS Analysis Concept Proposal Study Title: Risk for late effects of treatment in children newly diagnosed with mature B-cell non-hodgkin lymphoma: a report from the Childhood Cancer Survivor Study cohort
More informationPractice Based Evidence for Treatment of Pregnancy and Anthracycline Cardiomyopathy
Practice Based Evidence for Treatment of Pregnancy and Anthracycline Cardiomyopathy JEAN-BERNARD DURAND, M.D., FCCP, FACC,FACP,FHFSA,FAHA PROFESSOR OF MEDICINE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
More informationEffects of Comorbid Disease on Pre-treatment Neurobehavioral Functioning. Sunita K. Patel, PhD Assistant Professor. City of Hope Medical Center
Effects of Comorbid Disease on Pre-treatment Neurobehavioral Functioning. Sunita K. Patel, PhD Assistant Professor City of Hope Medical Center Duarte, California. Pre-Chemotherapy e e apycognitive Functioning
More informationChildhood Cancer Survivor Study Analysis Concept Proposal
Childhood Cancer Survivor Study Analysis Concept Proposal Title: Health outcomes among survivors of adolescent and young adult cancer in the Childhood Cancer Survivor Study. Working Group and Investigators:
More informationIs intensive inpatient cancer rehabilitation more effective than outpatient cancer rehabilitation?
Is intensive inpatient cancer rehabilitation more effective than outpatient cancer rehabilitation? Line Oldervoll, Anne Hokstad, Roy Nystad, Gro Bertheussen, Jon Arne Sandmæl, Liv Stenvågnes, Gro Haugen,
More informationHealth-Related Quality of Life in Children with Cancer
University of Tennessee Health Science Center UTHSC Digital Commons Theses and Dissertations (ETD) College of Graduate Health Sciences 8-205 Health-Related Quality of Life in Children with Cancer Tha'er
More informationChildhood Cancer Survivor Study Analysis Concept Proposal
Childhood Cancer Survivor Study Analysis Concept Proposal Title: Neurologic and Neurosensory Adverse Sequelae in Long-term Survivors of Childhood Brain Tumors: An Update and Expanded Risk Factor Analysis
More informationCancer Prevention & Control in Adolescent & Young Adult Survivors
+ Cancer Prevention & Control in Adolescent & Young Adult Survivors NCPF Workshop July 15-16, 2013 Patricia A. Ganz, MD UCLA Schools of Medicine & Public Health Jonsson Comprehensive Cancer Center + Overview
More informationCardiotoxicities of Cancer in Childhood Cancer Survivors
Cardiotoxicities of Cancer in Childhood Cancer Survivors Steven E. Lipshultz, MD Department of Pediatrics Wayne State University School of Medicine Children s Hospital of Michigan Detroit, MI, USA Stages
More informationAlexander Fosså, M.D. PhD.
Alexander Fosså, M.D. PhD. Current position: Senior Consultant, Department of Medical Oncology Oslo University Hospital Focus of work: - Malignant lymphoma - Chemotherapy, immunotherapy, radiotherapy -
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Schaapveld M, Aleman BMP, van Eggermond AM, et al. Second cancer
More informationThe course of fatigue in patients with gynecologic and breast cancer
Original Article J Gynecol Oncol Vol. 24, No. 3:280-286 pissn 2005-0380 eissn 2005-0399 The course of fatigue in patients with gynecologic and breast cancer Marie Vollrath 1, Markus Zenger 1, Susanne Singer
More informationR/R DLBCL Treatment Landscape
An Updated Analysis of JULIET, a Global Pivotal Phase 2 Trial of Tisagenlecleucel in Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Abstract S799 Borchmann P, Tam CS, Jäger U,
More informationEpidemiology/Biostatistics Working Group
Epidemiology/Biostatistics Working Group CCSS PI Meeting June 6-7, 2012 WG Committee Priorities Opportunity to publish methodology publications Evaluate and respond to methodological issues that arise
More informationChildhood Cancer Survivor Study Analysis Concept Proposal
Title: Multiple Subsequent Neoplasms Working Group and Investigators: Childhood Cancer Survivor Study Analysis Concept Proposal This proposed publication will be within the Second Malignancy Working Group
More information*Christian M. Carlsen, 1 Mette Mouridsen, 1 Ahmad Sajadieh, 1 Lars Køber, 2 Olav W. Nielsen 1 ABSTRACT BACKGROUND
USE OF N-TERMINAL NATRIURETIC PEPTIDE IN A REAL- WORLD SETTING OF PATIENTS ADMITTED WITH ACUTE DYSPNOEA AND THE IMPLICATION FOR TRIAGING PATIENTS IN THE EMERGENCY DEPARTMENT *Christian M. Carlsen, 1 Mette
More informationHeart failure (HF) is a complex clinical syndrome that results in the. impairment of the heart s ability to fill or to pump out blood.
Introduction: Heart failure (HF) is a complex clinical syndrome that results in the impairment of the heart s ability to fill or to pump out blood. As of 2013, an estimated 5.8 million people in the United
More informationFatigue Bigorio Professor Paddy Stone
Fatigue Bigorio 2013 Professor Paddy Stone Overview What is fatigue? How can fatigue be assessed? How can fatigue be treated? Guidelines? Fatigue is a subjective, unpleasant symptom which incorporates
More informationGONADAL, ADRENAL, ANDROGEN AND THYROID FUNCTIONS IN ADULTS TREATED FOR ACUTE LYMPHOBLASTIC LEUKEMIA
original paper Haematologica 1994; 79:141-147 GONADAL, ADRENAL, ANDROGEN AND THYROID FUNCTIONS IN ADULTS TREATED FOR ACUTE LYMPHOBLASTIC LEUKEMIA Fiorina Giona*, Luciana Annino*, Paola Donato, Michele
More informationChildhood Cancer Survivor Study Study Proposal: Male Health Questionnaire (MHQ) November 6, 2012
Childhood Cancer Survivor Study Study Proposal: Male Health Questionnaire (MHQ) November 6, 2012 1. STUDY TITLE: Perceptions of risk for Male Health Problems in childhood and adolescent cancer survivors:
More informationSusan P. D Anna MSN, APRN BC February 14, 2019
Is there Equal Opportunity in Heart Failure?? Susan P. D Anna MSN, APRN BC February 14, 2019 Disclosures: I have no financial disclosures. I am not an expert on this topic, but see a lot of women with
More informationCHILDHOOD CANCER SURVIVOR STUDY ANALYSIS CONCEPT PROPOSAL
CHILDHOOD CANCER SURVIVOR STUDY ANALYSIS CONCEPT PROPOSAL STUDY TITLE: Infertility and the use of fertility treatments in female survivors of childhood cancer. WORKING GROUP Chronic Disease INVESTIGATORS:
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationChildhood Cancer Survivor Study Analysis Concept Proposal November 12, 2010
Childhood Cancer Survivor Study Analysis Concept Proposal vember 12, 2010 1. Title: Radiation dose and benign thyroid conditions in the Childhood Cancer Survivor Study: analysis of radiation dose-response
More informationSurvival in Teenagers and Young. Adults with Cancer in the UK
Survival in Teenagers and Young Adults with Cancer in the UK Survival in Teenagers and Young Adults (TYA) with Cancer in the UK A comparative report comparing TYA cancer survival with that of children
More informationConflict of interest: none declared
The value of left ventricular global longitudinal strain assessed by three-dimensional strain imaging in the early detection of anthracycline-mediated cardiotoxicity C. Mornoş, A. Ionac, D. Cozma, S. Pescariu,
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Clinical perspective It was recently discovered that small RNAs, called micrornas, circulate freely and stably in human plasma. This finding has sparked interest in the potential
More informationDevelopment of a computerized tool for self-assessment of subjective symptoms that can be integrated in a Personal health record
Development of a computerized tool for self-assessment of subjective symptoms that can be integrated in a Personal health record Frode Laugen 1 1 Dept of cancer research and molecular medicine, Faculty
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/28958 holds various files of this Leiden University dissertation Author: Keurentjes, Johan Christiaan Title: Predictors of clinical outcome in total hip
More informationImaging of cardio-pulmonary treatment related damage. Radiotheraphy and Lung
Imaging of cardio-pulmonary treatment related damage Dr. Andrea Borghesi Dr. Emanuele Gavazzi Department of Radiology 2 University of Brescia Radiotheraphy and Lung The goal of radiation therapy (RT) is
More informationEndocrine Abnormalities in Aging Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study
Endocrine Abnormalities in Aging Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study Sogol Mostoufi-Moab, University of Pennsylvania Kristy Seidel, Fred Hutchinson Cancer Research
More informationThe Adolescent: A Patient at Risk: Ovarian Failure in Adolescent Cancer Survivors
The Adolescent: A Patient at Risk: Ovarian Failure in Adolescent Cancer Survivors Avner Hershlag MD Professor and Chief Center for Human Reproduction North Shore LIJ Hofsra university School of Medicine
More informationWHAT ARE PAEDIATRIC CANCERS
WHAT ARE PAEDIATRIC CANCERS INTRODUCTION Childhood cancers are RARE 0.5% of all cancers in the West Overall risk that a child will develop cancer during first 15 years of life is 1 in 450 and 1 in 600
More informationReduced health-related quality of life among Hodgkin's disease survivors: A comparative study with general population norms
Annals of Oncology 10: 7177, 1999. 1999 Kluwer Academic Publishers. Primed in the Netherlands. Original article Reduced healthrelated quality of life among Hodgkin's disease survivors: A comparative study
More informationLate Effects after Transplantation for Pediatric Severe Aplastic Anemia. Jean E. Sanders, M.D.
Late Effects after Transplantation for Pediatric Severe Aplastic Anemia Jean E. Sanders, M.D. Patient Characteristics Acquired Fanconi Number 137 15 Gender F:M 63:74 9:6 Etiology: Idiopathic Hepatitis
More informationThe Effect of Transition Clinics on Knowledge of Diagnosis and Perception of Risk in Young Adult Survivors of Childhood Cancer
The Effect of Transition Clinics on Knowledge of Diagnosis and Perception of Risk in Young Adult Survivors of Childhood Cancer Rohit G. Ganju, Emory University Ronica H. Nanda, Emory University Natia Esiashvili,
More informationAre palliative cancer patients willing and able to participate in a physical exercise program?
Palliative and Supportive Care ~2005!, 3, 281 287. Printed in the USA. Copyright 2005 Cambridge University Press 1478-9515005 $16.00 DOI: 10.10170S1478951505050443 Are palliative cancer patients willing
More informationReliability and Validity of the Pediatric Quality of Life Inventory Generic Core Scales, Multidimensional Fatigue Scale, and Cancer Module
2090 The PedsQL in Pediatric Cancer Reliability and Validity of the Pediatric Quality of Life Inventory Generic Core Scales, Multidimensional Fatigue Scale, and Cancer Module James W. Varni, Ph.D. 1,2
More informationChildhood Cancer Survivor Study (U24 CA55727)
CCSS An NCI-funded Resource Childhood Cancer Survivor Study (U24 CA55727) Report of the Chronic Disease Working Group Charles Sklar, M.D. CCSS Investigator Meeting Williamsburg, VA June 9-10, 2010 Chronic
More informationBendamustine for relapsed follicular lymphoma refractory to rituximab
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine for relapsed follicular lymphoma refractory to rituximab Bendamustine for relapsed follicular lymphoma refractory to rituximab Contents Summary 1
More information36 years childhood cancer registration in Germany. A network between clinics, clinical studies and the registry
(GCCR) 36 years childhood cancer registration in Germany A network between clinics, clinical studies and the registry Peter Kaatsch Claudia Spix, Desiree Grabow 40 years Swiss Childhood Scientifc symposium,
More informationChemotherapy- Associated Heart Failure. M. Birhan Yılmaz M.D, FESC Professor of Medicine Department of Cardiology Cumhuriyet University Sivas, TURKEY
Chemotherapy- Associated Heart Failure M. Birhan Yılmaz M.D, FESC Professor of Medicine Department of Cardiology Cumhuriyet University Sivas, TURKEY In last 20 years life-expectancy for patients with cancer
More informationImpact of pre-treatment symptoms on survival after palliative radiotherapy An improved model to predict prognosis?
Impact of pre-treatment symptoms on survival after palliative radiotherapy An improved model to predict prognosis? Thomas André Ankill Kämpe 30.05.2016 MED 3950,-5 year thesis Profesjonsstudiet i medisin
More informationMultiparametric Mapping for Assessment of Cancer Therapy Related Cardiotoxicity
Multiparametric Mapping for Assessment of Cancer Therapy Related Cardiotoxicity Cory V. Noel, M.D. Medical Director of CMR Pediatric Cardiology Outline What is meant by the term cardiotoxicity? Scope of
More informationJ Clin Oncol 25: by American Society of Clinical Oncology INTRODUCTION
VOLUME 25 NUMBER 15 MAY 20 2007 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E O R T Controlled Study of Fatigue, Quality of Life, and Somatic and Mental Morbidity in Epithelial Ovarian Cancer Survivors:
More information1. STUDY TITLE: Impact of Chronic Disease on Neurocognitive and Psychosocial Functions.
1. STUDY TITLE: Impact of Chronic Disease on Neurocognitive and Psychosocial Functions 2. WORKING GROUP AND INVESTIGATORS: 2.1. Working Groups: Psychology; Chronic Disease 2.2. Investigators: Neelam Jain
More informationChildhood Cancer Survivor Study Analysis Concept Proposal. Title: Analysis of Late Mortality by Treatment Era.
Childhood Cancer Survivor Study Analysis Concept Proposal Title: Analysis of Late Mortality by Treatment Era Working Group & Investigators: Greg Armstrong Todd Gibson Ann Mertens Wendy Leisenring YutakaYasui
More informationCHILDHOOD CANCER SURVIVOR STUDY- Analysis Concept Proposal. 1. TITLE: Tobacco Use Among Adult Siblings of Childhood Cancer Survivors
CHILDHOOD CANCER SURVIVOR STUDY- Analysis Concept Proposal 1. TITLE: Tobacco Use Among Adult Siblings of Childhood Cancer Survivors 2. WORKING GROUP INVESTIGATORS: This proposed study will be within the
More information